Boston Scientific Co. (NYSE:BSX) Shares Purchased by Allworth Financial LP

Allworth Financial LP boosted its holdings in Boston Scientific Co. (NYSE:BSX - Free Report) by 33.4% in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 11,244 shares of the medical equipment provider's stock after buying an additional 2,815 shares during the quarter. Allworth Financial LP's holdings in Boston Scientific were worth $1,004,000 at the end of the most recent quarter.

A number of other hedge funds have also bought and sold shares of the business. TFC Financial Management Inc. grew its stake in shares of Boston Scientific by 308.8% during the 4th quarter. TFC Financial Management Inc. now owns 278 shares of the medical equipment provider's stock valued at $25,000 after acquiring an additional 210 shares during the period. Global Wealth Strategies & Associates grew its stake in shares of Boston Scientific by 423.7% during the 4th quarter. Global Wealth Strategies & Associates now owns 309 shares of the medical equipment provider's stock valued at $28,000 after acquiring an additional 250 shares during the period. West Oak Capital LLC bought a new position in shares of Boston Scientific during the 4th quarter valued at approximately $29,000. Dunhill Financial LLC grew its stake in shares of Boston Scientific by 86.4% during the 3rd quarter. Dunhill Financial LLC now owns 328 shares of the medical equipment provider's stock valued at $28,000 after acquiring an additional 152 shares during the period. Finally, Values First Advisors Inc. bought a new position in shares of Boston Scientific during the 3rd quarter valued at approximately $28,000. Hedge funds and other institutional investors own 89.07% of the company's stock.

Insider Activity

In related news, EVP Arthur C. Butcher sold 14,010 shares of the firm's stock in a transaction dated Monday, November 25th. The stock was sold at an average price of $89.27, for a total transaction of $1,250,672.70. Following the sale, the executive vice president now owns 978 shares of the company's stock, valued at $87,306.06. This trade represents a 93.47 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, EVP Wendy Carruthers sold 6,983 shares of the firm's stock in a transaction dated Monday, December 2nd. The stock was sold at an average price of $90.78, for a total value of $633,916.74. Following the completion of the sale, the executive vice president now directly owns 29,308 shares of the company's stock, valued at approximately $2,660,580.24. This represents a 19.24 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 153,640 shares of company stock worth $15,718,289. Company insiders own 0.50% of the company's stock.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on BSX shares. JPMorgan Chase & Co. boosted their price objective on Boston Scientific from $100.00 to $110.00 and gave the company an "overweight" rating in a research note on Monday, December 16th. Deutsche Bank Aktiengesellschaft upgraded Boston Scientific from a "hold" rating to a "buy" rating and set a $108.00 price target for the company in a research note on Friday, January 10th. Truist Financial upped their price target on Boston Scientific from $100.00 to $110.00 and gave the stock a "buy" rating in a research note on Wednesday, December 18th. Stifel Nicolaus upped their price target on Boston Scientific from $100.00 to $115.00 and gave the stock a "buy" rating in a research note on Thursday, February 6th. Finally, Piper Sandler upped their price target on Boston Scientific from $95.00 to $115.00 and gave the stock an "overweight" rating in a research note on Monday, February 3rd. Two analysts have rated the stock with a hold rating, twenty-one have issued a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat.com, Boston Scientific currently has an average rating of "Moderate Buy" and an average target price of $107.39.

Boston Scientific Trading Down 1.2 %

NYSE:BSX traded down $1.23 during midday trading on Friday, hitting $104.13. 2,492,925 shares of the company traded hands, compared to its average volume of 5,939,795. The company has a current ratio of 1.08, a quick ratio of 1.02 and a debt-to-equity ratio of 0.41. The firm's fifty day moving average is $97.69 and its 200-day moving average is $89.06. Boston Scientific Co. has a 12-month low of $65.52 and a 12-month high of $107.17. The firm has a market capitalization of $153.67 billion, a P/E ratio of 83.33, a P/E/G ratio of 2.79 and a beta of 0.80.

Boston Scientific (NYSE:BSX - Get Free Report) last released its earnings results on Wednesday, February 5th. The medical equipment provider reported $0.70 earnings per share for the quarter, topping analysts' consensus estimates of $0.65 by $0.05. Boston Scientific had a return on equity of 17.80% and a net margin of 11.07%. On average, sell-side analysts predict that Boston Scientific Co. will post 2.85 EPS for the current year.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.